Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for psychiatrists, family medicine/primary care clinicians, internists, nurses, physician assistants, and other members of the health care team for patients with suicidal thoughts and behaviors.
The goal of this activity is for learners to be better able to describe novel, replicable genomic risk loci for suicidal thoughts and behaviors.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 02/10/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 2/10/2023
Valid for credit through: 2/10/2024, 11:59 PM EST
processing....
Worldwide annual incidence of suicide is more than 700,000 people. Among those aged 15 to 29 years of both sexes, suicide is the fourth leading cause of death.
The fastest US increase in suicide (nearly 50% since 2005) has been among military veterans. Suicidal thoughts and behaviors (SITB) are robust longitudinal predictors of suicide and are also rapidly increasing among US adults and veterans.
A genome-wide association study (GWAS) of SITB has identified significant cross-ancestry risk loci.
The findings provide further evidence of a genetic basis for SITB.
“It’s really important for us to continue to study the genetic risk factors for suicidal behaviors so we can really understand the biology and develop better treatments,” study investigator Allison E. Ashley-Koch, PhD, professor in the Department of Medicine at Duke University Medical Center, Durham, North Carolina, told Medscape Medical News.
The findings were published online December 14 in JAMA Psychiatry.
SITB Heritability
"[T]win studies indicate that heritability for SITB is between 30% and 55% [but] understanding of the molecular genetic basis of SITB remains limited,” the authors add.
To address this research gap, the investigators conducted a study of 633,778 US military veterans from the Million Veteran Program (MVP) cohort. Of these, 71% had European ancestry, 19% had African ancestry, 8% had Hispanic ancestry, and 1% had Asian ancestry. Just less than 10% of the sample was female.
Study participants donated a blood sample and agreed to have their genetic information linked to their electronic health record data.
From diagnostic codes and other sources, researchers identified 121,211 individuals with SITB. They classified participants with no documented lifetime history of suicidal ideation, suicide attempt, or suicide death as controls.
Rates of SITB differed significantly by ancestry: approximately 25% in those of African or Hispanic ancestry, 21% in those of Asian ancestry, and 17% in those with European ancestry. Rates also differed by age and sex: Those with SITB were younger and more likely to be female.
In addition to age and sex, covariates included “genetic principal components,” which Dr Ashley-Koch said accounts for combining data of individuals with different ethnic/racial backgrounds.
Through meta-analysis the investigators identified 7 genome-wide, significant cross-ancestry risk loci.
To evaluate whether the findings could be replicated, the researchers used the International Suicide Genetics Consortium (ISGC), a primarily civilian international consortium of roughly 550,000 individuals of mostly European ancestry.
The analysis showed that the top replicated cross-ancestry risk locus was rs6557168, an intronic single-nucleotide variant (SNV) in the ESR1 gene that encodes an estrogen receptor. Previous work “recently identified ESR1 as a causal genetic driver gene for the development of posttraumatic stress disorder [PTSD] and depression, both of which are risk factors for SITB among veterans,” the authors note.
The “second strongest replicated cross-ancestry locus was rs12808482, an intronic variant in DRD2, which encodes the D2 dopamine receptor subtype,” the authors write, noting that “DRD2 is highly expressed in brain tissue and has been associated with numerous psychiatric phenotypes.”
Research suggests that DRD2 is associated with other risk factors for SITB, such as schizophrenia, mood disorders, and attention deficit hyperactivity disorder (ADHD), but DRD2 could also contribute to suicide risk directly. The authors note that it is highly expressed in the prefrontal cortex, nucleus accumbens, substantia nigra, and hippocampus.
Outstanding Candidate Gene
The study revealed a cross-ancestry genome-wide significant (GWS) association for rs10671545, a variant in DCC, which is “also an outstanding candidate gene,” the investigators write.
They note that it is expressed in brain tissue, is involved in synaptic plasticity, axon guidance, and circadian entrainment, and has been associated with multiple psychiatric phenotypes.
The researchers also found what they called “intriguing” cross-ancestry GWS associations for the TRAF3 gene, which regulates type 1 interferon production. Many patients receiving interferon therapy develop major depressive disorder and suicidal ideation.
TRAF3 is also associated with antisocial behavior, substance use, and ADHD. “[L]ithium--a gold standard treatment for bipolar disorder shown to reduce suicide risk--modulates the expression of TRAF3,” the authors add.
Dr Ashley-Koch noted that the replication of these loci (ESR1, DRD2, TRAF3, and DCC) was in a population of mostly White civilians. “This suggests to us that at least some of the risk for suicidal thoughts and behaviors does cross ancestry and also crosses military and civilian populations.”
It was “exciting” that all 4 genes the study focused on had previously been implicated in other psychiatric disorders, said Dr Ashley-Koch. “What gave us a little more confidence, above and beyond the replication, was that these genes are somehow important for psychiatric disorders, and not any psychiatric disorders, but the ones that are also associated with a high risk of suicide behavior, such as depression, PTSD, schizophrenia and ADHD.”
“We need to take the next step, which is to try to understand how these genetic factors may impact risk and what else is happening biologically to increase that risk. Then once we do that, hopefully we can develop some new treatments,” she added.
“Valuable and Noble” Research
Commenting for Medscape Medical News, Elspeth Cameron Ritchie, MD, chief of psychiatry at Medstar Washington Hospital Center, Washington, DC, said that this kind of genetic research is “valuable and noble.”
Researchers have long been interested in risk factors for suicide among military personnel and veterans, said Dr Ritchie. Evidence to date suggests that being a young male is a risk factor, as is feeling excluded or not fitting into the unit, and drug or alcohol addiction.
Dr Ritchie noted that other psychiatric disorders, including schizophrenia, depression, and bipolar disorder, are at least partially inherited.
She noted that the study’s findings should not be used to discriminate against those who might have the identified genetic loci without clearer evidence of their impact: “If we were able to identify these genes, would we start screening everybody who joins the military to see if they have these genes, and how would that impact the ability to recruit or retain personnel?”
She agreed that additional work is needed to determine whether and how carrying these genes might affect clinical care. In addition, she pointed out that behavior is influenced not only by genetic load but also by environment. “This study may show the impact of the genetic load a little bit more clearly; right now, we tend to look at environmental factors.”
The study was supported by an award from the Clinical Science Research and Development service of the Veterans Health Administration’s Office of Research and Development. The work was also supported in part by the joint US Department of Veterans Affairs and US Department of Energy MVP CHAMPION program. Dr Ashley-Koch reported receiving grants from the Veterans Administration during the conduct of the study. Several other coauthors report relationships with industry, nonprofit organizations, and government agencies. The full list can be found with the original article. Dr Ritchie has reported no relevant financial relationships.
JAMA Psychiatry. Published online December 14, 2022.[1]